Baseline characteristics of study participants.
| n = 79 | IFS Treatment Group, n = 39 | Controls, n = 40 | p |
|---|---|---|---|
| Age, yrs; mean (SD) | 57.8 (13.8) | 58.5 (12.0) | 0.82 |
| Female, n (%) | 36 (92.3) | 35 (87.5) | 0.48 |
| White, n (%) | 35 (89.7) | 38 (97.4) | 0.17 |
| Married, n (%) | 21 (53.9) | 28 (70.0) | 0.14 |
| Income > 70K; n (%)* | 18 (51.4) | 18 (56.3) | 0.76 |
| Disease duration, yrs; mean (SD)† | 18.9 (10.8) | 13.9 (9.2) | 0.06 |
| Medications, n (%)‡ | |||
| Analgesics | 5 (13.5) | 4 (10.0) | 0.63 |
| NSAID | 13 (35.1) | 5 (12.5) | 0.02 |
| Corticosteroids | 8 (21.6) | 13 (32.5) | 0.28 |
| DMARD (nonbiological) | 26 (70.3) | 28 (70.0) | 0.98 |
| Biological therapy | 13 (35.1) | 16 (40.0) | 0.66 |
| Disease activity variables, mean (SD) | |||
| DAS28-CRP4 | 3.8 (1.4) | 3.0 (1.2) | 0.01 |
| RADAI joint score | 1.9 (1.5) | 1.5 (1.3) | 0.19 |
| Psychological variables, mean (SD) | |||
| Beck Depression Inventory | 10.2 (7.0) | 9.2 (7.4) | 0.55 |
| Spielberger State Trait Anxiety Index | 38.4 (8.9) | 36.5 (10.8) | 0.42 |
| Self-compassion scale | 20.9 (4.1) | 22.5 (4.5) | 0.10 |
| Lorig Self Efficacy | 68.2 (16.2) | 77.1 (16.0) | 0.02 |
| Functional variables, mean (SD) | |||
| SF-12 physical function | 51.9 (32.6) | 64.1 (32.8) | 0.11 |
| Visual analog scale | |||
| Pain | 43.2 (28.0) | 31.7 (27.2) | 0.07 |
| Sleep | 1.0 (0.9) | 0.8 (0.9) | 0.32 |
↵* Data missing on 8 controls and 4 IFS participants;
↵† Deleting 1 outlier;
↵‡ Data missing on 2 IFS participants. IFS: Internal Family Systems; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drug; DAS28-CRP4: Disease Activity Score-28-C-reactive Protein 4; RADAI: Rheumatoid Arthritis Disease Activity Index; SF-12: Short Form-12.